H
084990
vs
K
KOSPI 200
Over the past 12 months, Helixmith Co Ltd has underperformed KOSPI 200, delivering a return of -62% compared to KOSPI 200's +139% growth.
Stocks Performance
084990 vs KOSPI 200
Performance Gap
084990 vs KOSPI 200
Performance By Year
084990 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Helixmith Co Ltd
Glance View
Helixmith is a South Korean biopharmaceutical company that develops medicines based on gene therapy and other drug platforms. Its best-known work is around treatments for nerve damage and pain-related disorders, where it tries to make a patient’s own cells produce therapeutic proteins instead of relying only on repeated drug dosing. The company also works on other biotech drug candidates and related life-science development projects. The company makes money by advancing its own drug programs, partnering with other drug companies, and selling or licensing products and technology rights. In this business, the value comes from turning scientific research into approved medicines or licensed assets that can be sold in markets or shared with partners. That means Helixmith’s revenue model depends on drug development, licensing, and commercial drug sales rather than mass-market consumer products. What makes Helixmith’s role different is that it sits early in the pharmaceutical value chain: it is a drug creator, not a typical drug distributor. That makes the business more research-heavy and riskier than a standard manufacturer, but it also gives the company a chance to build value from proprietary science, patents, and platform technology if its programs succeed.
